• Customer Care
  • (888) 123-4567

News

At Rise Therapeutics, we develop targeted immunological-based biologics using a unique and proprietary oral delivery platform. We design and produce unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity, infection, and cancer.

Rise Therapeutics Prepares for Internal GMP Manufacturing Supported by the NIH’s Commercialization Readiness Program

Rockville, MD. Rise Therapeutics announced today that they have received funding associated with the National Institute of Health (NIH) Commercialization Readiness Program (CRP), enabling Rise to establish in house GMP manufacturing capabilities. The NIH’s CRP assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants or contracts.

Rise Therapeutics Hires Christian Furlan Freguia, PhD as Vice President of Research

Rockville, MD. Rise Therapeutics, a synthetic biology drug development company creating targeted immunological-based biologics using a unique and proprietary oral delivery platform, is pleased to announce the expansion of their executive leadership team. Rise welcomes Christian Furlan Freguia, Ph.D., to the position of Vice President of Research.

Rise Therapeutics Announces Lab Space Transition to Alexandria Real Estate Equities Facility

Rockville, MD. Rise Therapeutics announced today that they have moved to an Alexandria Real Estate Equities, Inc. (ARE) facility that provides a larger, more effective lab space located in the ARE Maryland life science companies cluster. The mixed laboratory/office space leased by Rise Therapeutics is part of a state-of-the-art research support facility Class A office/lab building located in Rockville, Maryland.

Rise Therapeutics Granted a Small Business Innovation Research Matching Grant from Montgomery County

Rockville, MD. Rise Therapeutics today announced that the Montgomery County Economic Development Fund’s subprogram, the SBIR/STTR Matching Grant Program, issued Rise Therapeutics a $25,000 matching grant to further their research project efforts in enhancing the effectiveness of immunotherapy in patients suffering from inflammatory bowel disease (IBD).

Rise Therapeutics awarded $2 Million to Develop a Novel, Immunological-Directed Microbiome-based Medicine for Treatment of Sjögren’s Syndrome

Rockville, MD. Rise Therapeutics announced today it was awarded a $2 million, multi-year grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program through the National Institute of Dental and Craniofacial Research (NIDCR). Grant funds will be used to develop a novel, immunologically enhanced probiotic-based therapeutic for the treatment of Sjögren’s syndrome (SS).

Rise Therapeutics Secures Funding to Develop a Novel Immunologically-Directed Probiotic for the Treatment of Inflammatory Bowel Disease

Rockville, MD. Rise Therapeutics today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) grant to fund the development of the novel engineered probiotic for the treatment of inflammatory bowel disease (IBD).This project builds on the research of co-collaborators Dr. Bikash Sahay and Dr. Ellen Zimmermann at The University of Florida.